{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:47:27Z","timestamp":1782312447128,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disease characterized by sequential progression of pathological events, such as aggregation of amyloid-\u03b2 proteins, followed by outward symptoms of cognitive impairments. Given that a combination of different therapeutic strategies often provides more rapid and effective outcomes in diverse areas of clinical treatment, we hypothesized that administration of anti-amyloid drugs with cognitive enhancers would result in synergistic effects in AD treatment. Here, we co-administered 4-(2-hydroxyethyl)-1-piperazinepropane-sulphonic acid (EPPS), an amyloid-clearing chemical, and donepezil, an acetylcholinesterase inhibitor, to determine whether they could serve complementary roles for each other in regards to AD treatment. We found that oral administration of these two molecules led to a rapid and consistent cognitive improvement in APP\/PS1 transgenic mice. Although there was no evidence for synergistic effects, our results indicated that EPPS and donepezil function complementary to each other without altering their individual effects. Thus, the combined use of disease-modifying and symptomatic relief drugs may be a promising approach in the treatment of AD.<\/jats:p>","DOI":"10.1038\/srep34165","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T11:02:26Z","timestamp":1477911746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rapid and sustained cognitive recovery in APP\/PS1 transgenic mice by co-administration of EPPS and donepezil"],"prefix":"10.1038","volume":"6","author":[{"given":"Hye Yun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjin Vincent","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongkeun K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungSoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"BFsrep34165_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot, P. N. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291, 317\u2013324, doi: 10.1001\/jama.291.3.317 (2004).","journal-title":"JAMA"},{"key":"BFsrep34165_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jama.289.2.210","volume":"289","author":"NH Trinh","year":"2003","unstructured":"Trinh, N. H., Hoblyn, J., Mohanty, S. & Yaffe, K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289, 210\u2013216 (2003).","journal-title":"JAMA"},{"key":"BFsrep34165_CR3","first-page":"233","volume":"18","author":"E Sinforiani","year":"2003","unstructured":"Sinforiani, E., Banchieri, L. M., Zucchella, C., Bernasconi, L. & Nappi, G. Cholinesterase inhibitors in Alzheimer\u2019s disease: efficacy in a non-selected population. Funct Neurol 18, 233\u2013237 (2003).","journal-title":"Funct Neurol"},{"key":"BFsrep34165_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370, 322\u2013333, doi: 10.1056\/NEJMoa1304839 (2014).","journal-title":"N Engl J Med"},{"key":"BFsrep34165_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370, 311\u2013321, doi: 10.1056\/NEJMoa1312889 (2014).","journal-title":"N Engl J Med"},{"key":"BFsrep34165_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr.","year":"2010","unstructured":"Jack, C. R., Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9, 119\u2013128, doi: 10.1016\/S1474-4422(09)70299-6 (2010).","journal-title":"Lancet Neurol"},{"key":"BFsrep34165_CR7","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1038\/ncomms9997","volume":"6","author":"HY Kim","year":"2015","unstructured":"Kim, H. Y. et al. EPPS rescues hippocampus-dependent cognitive deficits in APP\/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. Nat Commun 6, 8997, doi: 10.1038\/ncomms9997 (2015).","journal-title":"Nat Commun"},{"key":"BFsrep34165_CR8","doi-asserted-by":"publisher","first-page":"36275","DOI":"10.1074\/jbc.M703561200","volume":"282","author":"D Cao","year":"2007","unstructured":"Cao, D., Lu, H., Lewis, T. L. & Li, L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282, 36275\u201336282, doi: 10.1074\/jbc.M703561200 (2007).","journal-title":"J Biol Chem"},{"key":"BFsrep34165_CR9","first-page":"195","volume":"1","author":"J Knowles","year":"2006","unstructured":"Knowles, J. Donepezil in Alzheimer\u2019s disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid 1, 195\u2013219 (2006).","journal-title":"Core Evid"},{"key":"BFsrep34165_CR10","unstructured":"Bryan, K. J., Lee, H., Perry, G., Smith, M. A. & Casadesus, G. In Methods of Behavior Analysis in Neuroscience Frontiers in Neuroscience (ed Buccafusco, J. J. ) (2009)."},{"key":"BFsrep34165_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuroscience.2015.01.058","volume":"290","author":"HB Guo","year":"2015","unstructured":"Guo, H. B. et al. Donepezil improves learning and memory deficits in APP\/PS1 mice by inhibition of microglial activation. Neuroscience 290, 530\u2013542, doi: 10.1016\/j.neuroscience.2015.01.058 (2015).","journal-title":"Neuroscience"},{"key":"BFsrep34165_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1756285611404470","volume":"4","author":"D Galimberti","year":"2011","unstructured":"Galimberti, D. & Scarpini, E. Disease-modifying treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord 4, 203\u2013216, doi: 10.1177\/1756285611404470 (2011).","journal-title":"Ther Adv Neurol Disord"},{"key":"BFsrep34165_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000255578","volume":"28","author":"IA Lockhart","year":"2009","unstructured":"Lockhart, I. A., Mitchell, S. A. & Kelly, S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer\u2019s disease: systematic review of the \u2018real-world\u2019 evidence. Dement Geriatr Cogn Disord 28, 389\u2013403, doi: 10.1159\/000255578 (2009).","journal-title":"Dement Geriatr Cogn Disord"},{"key":"BFsrep34165_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00403864","volume":"21","author":"SR Wray","year":"1971","unstructured":"Wray, S. R. & Cowan, A. The behavioural effects of levallorphan, cyprenorphine (M285) and amphetamine on repeated Y-maze performance in rats. Psychopharmacologia 21, 257\u2013267 (1971).","journal-title":"Psychopharmacologia"},{"key":"BFsrep34165_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1037\/0097-7403.14.2.187","volume":"14","author":"MS Fanselow","year":"1988","unstructured":"Fanselow, M. S. & Tighe, T. J. Contextual conditioning with massed versus distributed unconditional stimuli in the absence of explicit conditional stimuli. J Exp Psychol Anim Behav Process 14, 187\u2013199 (1988).","journal-title":"J Exp Psychol Anim Behav Process"},{"key":"BFsrep34165_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1037\/0735-7044.106.2.274","volume":"106","author":"RG Phillips","year":"1992","unstructured":"Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106, 274\u2013285 (1992).","journal-title":"Behav Neurosci"},{"key":"BFsrep34165_CR17","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1364\/OL.32.001743","volume":"32","author":"Z Li","year":"2007","unstructured":"Li, Z., Herrmann, K. & Pohlenz, F. Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices. Opt Lett 32, 1743\u20131745 (2007).","journal-title":"Opt Lett"},{"key":"BFsrep34165_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 21, 372\u2013381 (2001).","journal-title":"J Neurosci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep34165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34165","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep34165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:12:27Z","timestamp":1672899147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep34165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,31]]}},"alternative-id":["BFsrep34165"],"URL":"https:\/\/doi.org\/10.1038\/srep34165","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]},"assertion":[{"value":"23 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34165"}}